Cytokinetics INC Form 4 insider transactions

Director Wendell Wierenga acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics Inc.

Director Nancy Wysenski acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics Inc.

Cytokinetics EVP of Research & Development, Fady Ibraham Malik, acquired 3,500 shares of common stock and sold 3,500 stock options.

Cytokinetics Inc. reports that President & CEO Robert I. Blum acquired 7,500 shares of common stock on May 14, 2026, for $77.92 per share.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised 3,500 stock options and sold the resulting shares.

Cytokinetics Director Wendell Wierenga engaged in stock transactions, acquiring shares via an option exercise and subsequently selling a portion of his holdings.

Cytokinetics EVP, Chief Financial Officer, Lee Sung, reported a transaction involving the purchase of common stock.

Andrew Callos, EVP and Chief Commercial Officer at Cytokinetics Inc., sold 11,333 shares of common stock on May 5, 2026, under a pre-arranged 10b5-1 trading plan.

Cytokinetics EVP Andrew Callos acquired company stock and disposed of stock options on May 1, 2026, according to a Form 4 filing.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised options and sold 3,500 shares of common stock.

Director Nancy Wysenski acquired 95 shares of Cytokinetics common stock through the company's Director Equity in Lieu of Cash Retainer Program.

Director Wendell Wierenga acquired 95 shares of Cytokinetics common stock as part of a director equity compensation program.

Director Edward M. Kaye acquired 191 shares of Cytokinetics common stock as part of a director equity compensation program.

Director John T. Henderson acquired 325 shares of Cytokinetics common stock through the company's equity-in-lieu-of-cash program.

Director Robert Arthur Harrington acquired 191 shares of Cytokinetics common stock through the company's Director Equity in Lieu of Cash Retainer Program.

Director James M. Daly acquired 191 shares of Cytokinetics common stock as part of the company's Director Equity in Lieu of Cash Retainer Program.

EVP and Chief Commercial Officer Andrew Callos sold 7,449 shares of Cytokinetics common stock on April 15, 2026.

Cytokinetics President and CEO Robert I. Blum sold 7,500 shares of common stock on April 15, 2026.

Cytokinetics EVP of Research & Development, Fady Ibraham Malik, reported transactions involving the acquisition and sale of common stock and stock options.

Cytokinetics President and CEO Robert I. Blum filed a Form 4 indicating a planned sale of 7,500 common shares on April 1, 2026, under a Rule 10b5-1 plan.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, reported the sale of 3,639 common shares at $65 per share, executed under a pre-arranged 10b5-1 trading plan.

Cytokinetics' EVP and CFO, Sung Lee, sold 4,935 shares of common stock at $62.15 per share to cover tax withholding obligations related to RSU vesting.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, sold 8,542 shares of common stock to cover tax withholding obligations from RSU vesting.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, sold 12,033 shares of common stock to satisfy tax withholding obligations from RSU vesting.

Cytokinetics' President & CEO, Robert I. Blum, sold shares to cover tax withholding obligations from RSU vesting.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, sold 1,930 shares of common stock for $62.07 per share in a pre-planned transaction.

Cytokinetics' President and CEO, Robert I. Blum, received annual equity awards including restricted stock units and stock options.

Cytokinetics' EVP and Chief Commercial Officer, Andrew Callos, was granted significant equity awards, including restricted stock units and stock options, effective March 15, 2026.

Cytokinetics' Chief Legal & Admin Officer, Jeffrey Hessekiel, was granted significant equity awards including restricted stock units and stock options on March 15, 2026.

CYTOKINETICS' EVP of Research & Development, Fady Ibraham Malik, received significant equity awards including restricted stock units and stock options.